Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 3/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | WRN | Q14191 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7930452 | 0.85 | GRM4 (0.54) | GRM4KCNH2ARAKT1BLM | |
| SCHEMBL24061321 | 0.85 | TSHR (0.61) | GRM4KCNH2ARAKT1BLM | |
| SCHEMBL31703118 | 0.85 | GRM4 (0.58) | GRM4KCNH2ARAKT1BLM | |
| SCHEMBL4224722 | 0.82 | POLB (0.50) | ALDH1A1HPGDCYP1A2CYP2C19KDM4E | |
| SCHEMBL4900667 | 0.81 | GRM4 (0.59) | GRM4KCNH2ARAKT1BLM | |
| SCHEMBL8481692 | 0.80 | TSHR (0.59) | TSHRALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL3554749 | 0.80 | ALDH1A1 (0.63) | GRM4BLMWRNALDH1A1HPGD | |
| SCHEMBL29824380 | 0.77 | GRM4 (0.56) | GRM4KCNH2BLMWRNALDH1A1 | |
| SCHEMBL12777490 | 0.77 | GRM4 (0.56) | GRM4ARBLMWRNALDH1A1 | |
| SCHEMBL3008351 | 0.77 | GRM4 (0.56) | GRM4KCNH2ARBLMWRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326027-A1 | N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090326027-A1 | N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090326027-A1 | N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| WO-2007104775-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | SLC18A2, SLC1A2, SLC1A1 | GRM4 106/4885KCNH2 2771/4885AR 3345/4885 |
| US-20090326027-A1 | N-Phenyl-2-0X0-1,4-Diazaspiro [4.5] Dec-3-EN-1-YL Acetamide Derivatives And Their Use As Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC6A3 | GRM4 152/4885KCNH2 1654/4885AR 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.